Presence of 1q21 Gain and Amplification May be Associated With Poorer Outcomes in Daratumumab-treated Multiple Myeloma Patients.
Lim KJC, Wellard C, Moore E, Ninkovic S, Chng WJ, Spencer A, Mollee P, Hocking J, Ho PJ, Janowski W, Kim K, McCaughan G, Dun K, McQuilten ZK, Chen F, Quach H.
Lim KJC, et al. Among authors: kim k.
Clin Lymphoma Myeloma Leuk. 2024 Nov 9:S2152-2650(24)02402-9. doi: 10.1016/j.clml.2024.11.002. Online ahead of print.
Clin Lymphoma Myeloma Leuk. 2024.
PMID: 39616008
No abstract available.